Rxwire
In the news · 48h FDA 37 Eli Lilly 17 Roche 9 Merck & Co. (MSD) 7 Johnson & Johnson 4 AstraZeneca 3 Novo Nordisk 3 AbbVie 2
Approvals & regulatory · first seen 2h ago, updated 2h ago

Grail multicancer detection test wins FDA advisers’ backing

1 outlet FDA

Panel members said the first-of-a-kind blood test should not be used to replace medical guideline-recommended cancer screenings, however.

Summary from BioPharma Dive.

Coverage 1 article · 1 outlet

  1. BioPharma Dive
    Grail multicancer detection test wins FDA advisers’ backing